Need a report that reflects how COVID-19 has impacted this market and its growth?
France In-Vitro Diagnostic Market is expected to witness a CAGR of 7.5% over the forecast period (2022 - 2027).
The emergence of the COVID-19 pandemic has had an adverse effect on the world economy and the healthcare system. The lockdown has affected the supply chain of, drugs, medical devices, and products. However, the outbreak of COVID-19 is expected to positively impact the market, as in vitro diagnostics involve the testing of various biological samples. This is expected to aid the diagnosis of infectious diseases, such as COVID-19. For instance, in an article published by the Multidisciplinary Digital Publishing Institute, in April 2020, titled 'In Vitro Diagnostics Assays For COVID-19: Recent Advances and Emerging Trends', it has been observed that the in-vitro diagnostic tests have proven to be crucial in the fight against COVID-19. In addition, as per the same source, the ongoing research efforts and advances in complementary technologies pave the way to a new point of care for in-vitro diagnostic assays.
Certain factors that are also propelling the market growth are the rising incidence of chronic diseases, increasing awareness and acceptance of personalized medicine and companion diagnostics, and the increasing use of point-of-care (POC) diagnostics.
The rising burden of chronic diseases such as infectious diseases, cardiovascular diseases, cancers, and others is the main factor driving the demand for the in-vitro diagnostics market over the forecast period. For instance, according to 2022 statistics published by the International Diabetes Federation, in the 10th edition of 2021, about 3,942.9 thousand people were living with diabetes, in 2021, in France. In addition, as per the same source, this number is projected to reach 4,184.9 thousand by 2030 and 4,225.7 thousand by 2045. Additionally, according to Globocan 2020 fact sheet, 467,965 new cancer cases were reported in France, in 2020, while the number of prevalent cases of cancer in five years was 1,501,881. The same report projected that 579,388 new cancer cases are expected to be diagnosed in France by 2040. Thus, the growing number of chronic diseases among the population is expected to increase the demand for better treatment and diagnostic equipment, which in turn is anticipated to increase the market growth over the forecast period. Thus, COVID-19 has significant impact on the market growth.
Furthermore, the increasing use of point-of-care diagnostics in the country as well as initiatives taken to increase the awareness and testing for chronic diseases is also contributing to the growth of the market. For instance, In March 2022, France launched a new colon-cancer testing system for people aged 50-74 years. Also, in July 2020, Eurofins Technologies launched new, rapid point-of-care testing devices aimed at testing for the presence of COVID-19, the respiratory disease caused by the coronavirus.
However, the stringent regulations related to diagnostic equipment and devices are impeding the market growth over the forecast period.
Scope of the report
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as diabetes, cancer, and others. The France In-Vitro Diagnostics Market is segmented by By Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, and Other Techniques), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Devices, Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, and Other Applications) and End-users (Diagnostic Laboratories, Hospitals, and Clinics and Other End-users). The report offers the value (in USD million) for the above segments.
|By Test Type|
|Disposable IVD Devices|
|Reusable IVD Devices|
|Hospitals and Clinics|
Key Market Trends
Infectious Disease Segment Expects to Register a High CAGR in the France In-Vitro Diagnostics Market Over the Forecast Period
The infectious diseases segment is expected to witness significant growth in the in-vitro diagnostics market over the forecast period owing to factors such as the rising prevalence of infectious diseases and rising awareness among the population and growing demand for point-of-care diagnostics.
The increasing prevalence of infectious diseases such as HIV/AIDS, tuberculosis, hepatitis B, hepatitis C, and others are the key factor driving the demand for in-vitro diagnostics market in the country. For instance, according to the World Data Atlas, the incidence of tuberculosis in France was 8.2 cases per 100,000 people, in 2020. Additionally, as per the data published by the World Health Organization, as of August 2022, 14,820 confirmed cases of COVID-19 were reported in France on 22nd August 2022 as compared to 6.331 confirmed cases of COVID-19 on 17th August 2022. Thus, the rising number of coronavirus infections among the population increases the demand for early diagnosis and effective treatment options, thereby propelling the market growth.
Moreover, growing awareness regarding the early diagnosis and treatment, and increasing company focus on developing effective diagnostic products for detecting various infectious diseases are expected to boost the market growth over the forecast period. For instance, in September 2020, GeneStore France launched GeneStore Détection Expert, a One Step Real Time Reverse Transcription (OSRTRT) PCR Kit for Qualitative Detection of SARS CoV 2.
Thus, owing to the aforementioned factors, the studied segment is expected to grow over the forecast period.
To understand key trends, Download Sample Report
France is a developed region with a well-structured healthcare system. As a result, many players in the in-vitro diagnostics market are present in the country. Thus, the in-vitro diagnostic market in France is fairly fragmented with the presence of local players competing in the market. Some of the players in the market include Abbott Laboratories, F. Hoffmann-La Roche AG, QIAGEN N.V., Siemens Healthineers AG, Thermo Fischer Scientific Inc., BioMerieux and Becton, Dickinson and Company.
- In May 2022, THERADIAG launched two additional kits in its i-Tracker tests range. The company is extending its range with two additional i-Tracker test kits: i-Tracker Certolizumab and i-Tracker Anti-Certolizumab, all adapted to the i-Track.
- In March 2021, BioMérieux received the CE marking of its innovative and fully automated test VIDAS TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.2.3 Increasing Use of Point-of-care (POC) Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD million)
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.4 Other Techniques
5.2 By Product
5.2.3 Other Product
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.5 Other Applications
5.5 By End-users
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals and Clinics
5.5.3 Other End-users
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Danaher Corporation
6.1.6 F. Hoffmann-La Roche AG
6.1.7 QIAGEN N.V.
6.1.8 Siemens Healthcare GmbH
6.1.9 Sysmex Corporation
6.1.10 Thermo Fischer Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The France In-Vitro Diagnostics Market market is studied from 2019 - 2027.
What is the growth rate of France In-Vitro Diagnostics Market?
The France In-Vitro Diagnostics Market is growing at a CAGR of 7.5% over the next 5 years.
Who are the key players in France In-Vitro Diagnostics Market?
Thermo Fischer Scientific Inc, QIAGEN N.V., Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Abbott Laboratories are the major companies operating in France In-Vitro Diagnostics Market.